Celgene wins Chinese regulatory OK for Revlimid

Mon Feb 11, 2013 7:35pm IST

Related Topics

Stocks

   

(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.

Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.

Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.

In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.

Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.

It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.

(Reporting By Debra Sherman; Editing by Gerald E. McCormick)

FILED UNDER:

Health

Reuters Showcase

Micromax Stake

Micromax Stake

SoftBank-led group in talks to buy stake in Micromax - sources  Full Article 

Plane Crash

Plane Crash

Co-pilot appears to have crashed Germanwings plane on purpose, prosecutor says  Full Article 

Airwaves Auction

Airwaves Auction

Top three mobile operators spend $13.6 bln in airwaves auction  Full Article 

Twitter Video App

Twitter Video App

Twitter launches video streaming app Periscope  Full Article 

Yemen Attacked

Yemen Attacked

Yemeni leader Hadi leaves country as Saudi Arabia keeps up air strikes on Houthi rebels  Full Article 

FIFA Politics

FIFA Politics

FIFA taking the wrong approach to development, says Prince Ali   Full Article 

Downton Abbey

Downton Abbey

Downton Abbey to wind up after sixth season, producer says  Full Article 

Photo

Amazon Fashion

Indian designers will create new products for online shoppers: Amazon India fashion head  Full Article 

Australia Beat India

Australia Beat India

Smith shines as Australia down India to reach final  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage